Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
October introduced a spread of developments within the administration of blood cancers, from early-stage a number of myeloma to new mobile therapies...
The ultimate outcomes of the RATIONALE-315 trial confirmed that including immunotherapy earlier than and after surgical procedure helped adults with resectable non-small...
Within the part 3 ASCENT-07 trial, Trodelvy (sacituzumab govitecan-hziy) given as the primary therapy after endocrine remedy didn't enhance progression-free survival in...
